Lemaitre Vascular (LMAT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Daniel Stauder from JMP Securities reiterated a Buy rating on the stock and has a $113.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Daniel Stauder has given his Buy rating due to a combination of factors that highlight Lemaitre Vascular’s strong financial performance and promising future prospects. The company demonstrated a 14% organic sales growth and a 30% improvement in EPS in the final quarter of 2024, along with a notable expansion in operating margins. These results, although slightly below revenue expectations, were in line with EPS forecasts and set a positive tone for the upcoming year.
Looking forward, the initial guidance for 2025 suggests a 10% year-over-year increase in organic sales, the highest in recent years, and an anticipated operating margin expansion to 25%. Additionally, price increases and strategic expansions in sales force and product approvals are expected to further bolster growth. The decision to raise the price target to $113 reflects confidence in Lemaitre Vascular’s ability to maintain its momentum and capitalize on its market position, supported by a strong cash flow and profitability profile.
According to TipRanks, Stauder is a 5-star analyst with an average return of 67.0% and a 73.91% success rate. Stauder covers the Healthcare sector, focusing on stocks such as Atricure, Artivion, and Lemaitre Vascular.
In another report released on February 14, Lake Street also reiterated a Buy rating on the stock with a $105.00 price target.